1592U89 (use abacavir)
(-)-2',3'-dideoxy-5-fluoro-3'-thiacytidine - Feb., p. 34; Nov., p. 332
2'-beta-fluoro-2',3'-dideoxyadenosine - Apr., p. 101
3TC (use Epivir-HIV for HIV treatment, Epivir-HBV for hepatitis B)
abacavir sulfate (Ziagen) - Feb., p. 44; Mar., p. 70, 74; July, p. 199, 203; Oct., p. 298, 299; Dec., p. 355
acyclovir - Apr., p. 108; Aug., p. 231, 238; Oct., p. 298; Nov., p. 325
adefovir dipivoxil (Preveon) - Apr., p. 101, 103; July, p. 201; Sep., p. 265; Nov., p. 323; Dec., p. 360
adenine arabinoside (ara-A) - Mar., p. 70
AG7088 - Oct., p. 299; Dec., p. 365
Agenerase (use amprenavir)
AIDSVAX - Mar., p. 71; June, p. 161; Sep., p. 268
Alferon N - Feb., p. 39; Mar., p. 69; Apr., p. 99
alitretinoin - June, p. 172
ALVAC HIV gp160 vaccines - Feb., p. 37; May, p. 133
AMD3100 - Sep., p. 267
Ampligen - Apr., p. 104; Nov., p. 333
amprenavir (Agenerase) - Mar., p. 68; June, p. 167; July, p. 199; Oct., p. 291, 301; Nov., p. 330; Dec., p. 360
androstane derivatives - Oct., p. 293
antisense agents - Feb., p. 41; Mar., p. 65, 71; Apr., p. 99; May, p. 143; June, p. 169; July, p. 207; Sep., p. 270; Dec., p. 367
Antivirogram test - May, p. 139
arylene bis-methyl ketones - July, p. 200
AZT - Feb., p. 33; Apr., p. 108, 97, 98; Aug., p. 233; Dec., p. 357
BCH-10652 - June, p. 169
bicyclams - Sep., p. 267
Bio-Hep-B - June, p. 170
bis(POC)PMPA - Mar., p. 73; Oct., p. 300
bis(POM)PMEA - Apr., p. 103
bursal disease virus vaccines - June, p. 168
BV-araU - June, p. 170
(+)-calanolide A - Mar., p. 72
CD4 blockers - July, p. 202
cesarean sections - Sep., p. 265
chemokines - July, p. 196
chitosan adjuvant - Sep., p. 267
CI-1012 - Dec., p. 364
cidofovir (Vistide) - Feb., p. 44; Apr., p. 106
CNI-H0294 - July, p. 200
CNI-H1194 - July, p. 200
Combivir (AZT plus Epivir-HIV) - Feb., p. 33; Apr., p. 108
Crixivan (use indinavir)
cyclophilin A antibodies - July, p. 200
cytomegalovirus antibody, humanized - Feb., p. 37
cytomegalovirus immune globulin [CytoGam] - Dec., p. 366
cytomegalovirus vaccines - May, p. 141; Sep., p. 269
cytosine arabinoside (ara-C) - Feb., p. 44; June, p. 171
D4T (Zerit) - Feb., p. 33; Mar., p. 74; Aug., p. 230, 233
DAPD - Aug., p. 228
DDC (Hivid) - Feb., p. 33
DDI (Videx) - Feb., p. 33; Aug., p. 230, 233
delavirdine mesylate (Rescriptor) - Mar., p. 74
dendritic cells - June, p. 171
dengue virus vaccines - Dec., p. 359
didehydro-dideoxy-5-fluorocytidine (D-D4FC) - Aug., p. 236
DISC vaccines - Feb., p. 42; May, p. 130
DMP-450 - Feb., p. 44
Ebola virus DNA vaccines - Feb., p. 40
efavirenz (Sustiva) - Feb., p. 39; Mar., p. 74; May, p. 140; June, p. 167; Aug., p. 232; Oct., p. 289; Dec., p. 366
Engerix-B - Apr., p. 109; Sep., p. 268; Dec., p. 358
Epivir-HBV - Feb., p. 34; May, p. 131; June, p. 174; Aug., p. 237; Sep., p. 264, 270; Nov., p. 333, 334; Dec., p. 353
Epivir-HIV - Feb., p. 33; Apr., p. 108; May, p. 138; June, p. 174; Aug., p. 233, 234; Sep., p. 270
F-ddA - Apr., p. 101
famciclovir (Famvir) - Apr., p. 109; May, p. 134; June, p. 172; Nov., p. 330
FLU OIA - May, p. 140; Dec., p. 366
FluMist - Mar., p. 71; May, p. 133; Aug., p. 227; Sep., p. 262
Fluogen - Mar., p. 70; Sep., p. 268
fomivirsen sodium (Vitravene) - Mar., p. 65; Apr., p. 99; Sep., p. 257
foscarnet prodrugs - Mar., p. 77
foscarnet sodium (Foscavir) - Dec., p. 365
Fortovase (use saquinavir)
FTC - Feb., p. 34; Nov., p. 332
GAPDH promoters - Sep., p. 271
GeneDrugs - Aug., p. 229
GENEVAX vaccines - Mar., p. 78; May, p. 137
Genvir - Nov., p. 325
GM-CSF (Leukine) - Mar., p. 67; Aug., p. 228; Oct., p. 301
GS 4104 - July, p. 200; Oct., p. 292
H-BIG (use hepatitis B immune globulin)
HAART (highly active antitretroviral therapy; used broadly for various triple and other HIV drug combinations) - Mar., p. 66, 68, 69, 74; June, p. 164, 167; July, p. 196, 197, 199, 201, 204; Aug., p. 225, 228, 233, 235, 236; Oct., p. 291, 295, 297, 298, 299; Nov., p. 321, 323, 327, 329, 331; Dec., p. 360
HBY 097 - Mar., p. 77
HE2000 - Oct., p. 293
HE317 - Oct., p. 293
Hepagene - Nov., p. 331; Dec., p. 357
Hepatico - June, p. 172
Hepatitis B Antibody, Human Anti- - Feb., p. 37
hepatitis B immune globulin (H-BIG) - May, p. 139; Nov., p. 333
hepatitis B virus DNA vaccines - Apr., p. 100
hepatitis B virus monoclonal antibody - June, p. 166
hepatitis B virus vaccines - Mar., p. 78; Apr., p. 109; June, p. 170; Sep., p. 268; Nov., p. 331; Dec., p. 357, 358
hepatitis C virus helicase - Feb., p. 39
hepatitis C virus immune globulin - Apr., p. 105; Sep., p. 263
hepatitis C virus PCR - July, p. 206
hepatitis C virus protease inhibitors - May, p. 141; Aug., p. 240
hepatitis C virus vaccines - Apr., p. 108; Sep., p. 263
herpes simplex virus type 2 (HSV-2) vaccines - May, p. 130
HGP-30/HGP-30W - Aug., p. 237; Oct., p. 301
histamine receptor agonists - Feb., p. 36; Apr., p. 107; June, p. 169
HIV chemokine/co-receptor inhibitors - Feb., p. 38, 41
HIV DNA vaccines - Apr., p. 100; May, p. 137
HIV gene therapy - May, p. 143; July, p. 195
HIV gene therapy vaccines - Feb., p. 35, 42
HIV immune globulin - June, p. 165
HIV p17 peptide vaccines - Aug., p. 237; Oct., p. 301
HIV p24 vaccines - Mar., p. 67, 74
HIV protease inhibitors - Feb., p. 44; Mar., p. 66, 71
HIV ribozyme gene therapy - Feb., p. 43; Apr., p. 107
HIV vaccines - Feb., p. 44; Mar., p. 70, 71; May, p. 133, 138; June, p. 161; Aug., p. 239; Sep., p. 264, 268; Dec., p. 362
HIV vaccines, immunotherapeutic - Feb., p. 43; Mar., p. 70; Apr., p. 106; June, p. 163; Nov., p. 327
HIV vaccines, live - Sep., p. 261
HIV vaccines, poxvirus vectors - Feb., p. 37; May, p. 133; Sep., p. 267
HIV vaccines, Salmonella vector - Apr., p. 105
HIV zinc finger inhibitors - Dec., p. 364
HIV-1 Western Blot, urine - July, p. 204
HIV-IT (V) - May, p. 138
Hivid (use DDC)
HPMPC - Apr., p. 106
human chorionic gonadotropin (hCG) - Apr., p. 100
human papillomavirus vaccines - Feb., p. 38; May, p. 143
HveC - July, p. 202
hydroxyurea - Aug., p. 230; Dec., p. 360
hypericin - Feb., p. 40
imiquimod derivatives - Dec., p. 364
indinavir sulfate (Crixivan) - Mar., p. 74, 75; Aug., p. 233; Oct., p. 295, 296
Infergen (use interferon, consensus)
influenza diagnostics - Dec., p. 366
influenza vaccines - Mar., p. 70, 71, 73; May, p. 133, 141; June, p. 170; July, p. 202; Aug., p. 227; Sep., p. 262, 267, 268; Oct., p. 300; Dec., p. 361
inosine monophosphate dehydrogenase inhibitors - Oct., p. 292
interferon alfa-2b (Intron A) - Feb., p. 36; Apr., p. 107; May, p. 129, 138; June, p. 169; Aug., p. 229; Sep., p. 267; Oct., p. 293; Nov., p. 325, 327, 333; Dec., p. 354
interferon alpha - July, p. 206
interferon alpha, transgenic - Aug., p. 229
interferon, leukocyte - Feb., p. 39; Mar., p. 69; Apr., p. 107, 99; Aug., p. 238; Oct., p. 300; Dec., p. 365
interferon, low-dose oral - Apr., p. 106; May, p. 140; Oct., p. 297; Nov., p. 332
interferon, PEGylated - Dec., p. 360
interleukin-1 beta adjuvant - Mar., p. 73; Aug., p. 238; Nov., p. 330
interleukin-2 (IL-2; Proleukin) - Apr., p. 106; Aug., p. 234; Nov., p. 323
Intron A (use interferon alfa-2b)
Invirase (use saquinavir)
ISIS 13312 - Feb., p. 41
Japanese encephalitis virus vaccines - July, p. 198; Dec., p. 359
JE-2147 - July, p. 205
KNI-764 (use JE-2147)
L-carnitine - July, p. 202
L-FMAU - Mar., p. 76
lamivudine (use Epivir-HIV for HIV and Epivir-HBV for hepatitis B)
Leishmania elongation Initiation Factor (LeIF) adjuvant - Feb., p. 42
Leukine (use GM-CSF)
leukocyte removal - Aug., p. 238
Lidakol (use n-docosanol)
lodenosine - Apr., p. 101
marine drugs - Nov., p. 328
Maxamine - Feb., p. 36; Apr., p. 107; June, p. 169
MDI-P - Oct., p. 294
measles vaccines - Apr., p. 108
MEDI-493 (use palivizumab)
MEDI-501 - Oct., p. 297
MF59 adjuvant - Oct., p. 303
microbicides, intravaginal - June, p. 172; Nov., p. 334
MKC-442 - Aug., p. 228; Dec., p. 360
modified vaccinia Ankara (MVA) virus vectors - Dec., p. 362
monoclonal antibodies, humanized - Sep., p. 270; Oct., p. 303
monophosphoryl lipid A (MPL) - Dec., p. 358
MTCH-24 - July, p. 202
MTH-68/B - June, p. 168
n-docosanol (Lidakol) - Feb., p. 37; Oct., p. 291; Nov., p. 333
Nabi 3700.001 - June, p. 173; Oct., p. 300
Nabi-Civacir - Apr., p. 105; Sep., p. 263
needleless delivery systems - Apr., p. 100
nelfinavir (Viracept) - Feb., p. 41; Mar., p. 69, 72; Sep., p. 267; Nov., p. 331
neuraminidase inhibitors - Oct., p. 296
nevirapine (Viramune) - Mar., p. 72, 74; June, p. 167; Aug., p. 225; Oct., p. 301
Norvir (use ritonavir)
Novasomes - Mar., p. 73; May, p. 143
nucleoside analogs - Nov., p. 324
Omniferon - Apr., p. 107; Oct., p. 300; Dec., p. 365
OST 577 - Feb., p. 37
Ostavir - June, p. 166
Oxoferin - Nov., p. 331
ozone - Nov., p. 332
P-glycoproteins - Mar., p. 71
paclitaxel - Feb., p. 44
palivizumab (Synagis) - Feb., p. 40; July, p. 193; Sep., p. 267, 269; Oct., p. 301
Panretin gel - June, p. 172
Papirines - May, p. 135
Pegasys - Dec., p. 360
PEN203 - May, p. 135
pentafuside - Feb., p. 35; May, p. 140
Peptimers - Mar., p. 67
phosphazide - Sep., p. 265
phosphonoformate, 1-O-octadecyl-sn-glycero-3- - Mar., p. 77
phosphorothioate oligonucleotides - Sep., p. 270
photinactivation - Feb., p. 36
PLAS+SD (use plasma, viral inactivated)
plasma, viral inactivated - Feb., p. 36; Apr., p. 109; May, p. 142; Dec., p. 365
platelets, viral inactivated - Feb., p. 36
pleconaril - Nov., p. 326
PNU-140690 - Mar., p. 66; Aug., p. 235
poliovirus vaccines - Feb., p. 40; Dec., p. 364
polyphemusin II - Mar., p. 74
Preveon (use adefovir)
PRO 2000 Gel - June, p. 172; Nov., p. 334
Proleukin (use interleukin-2)
Quantiplex HIV-1 RNA 3.0 assay - Aug., p. 237
quinoxalines - Mar., p. 77
rabies vaccines - May, p. 141; Aug., p. 230
ranitidine - Feb., p. 42
Rebetron Combination Therapy - May, p. 129, 138; Aug., p. 235; Sep., p. 266; Oct., p. 293; Nov., p. 327, 333; Dec., p. 354
Relenza (use zanamivir)
Remune - Feb., p. 43; Mar., p. 70; Apr., p. 106; June, p. 163; Nov., p. 327
Rescriptor (use delavirdine)
RespiGam - Feb., p. 40
respiratory syncytial virus Mab, humanized - Feb., p. 40; July, p. 193; Sep., p. 267, 269; Oct., p. 301
Reticulose - May, p. 138; June, p. 171
Retrovir (use AZT)
Reversionex - Oct., p. 293
rhinovirus 3C protease inhibitors - Dec., p. 365
rhinovirus diagnostics - Nov., p. 333
ribavirin - May, p. 129, 138; Aug., p. 235; Oct., p. 293; Nov., p. 327, 333; Dec., p. 354
ring expanded nucleosides/nucleotides - June, p. 173; Oct., p. 300
ritonavir (Norvir) - Mar., p. 69; Aug., p. 226, 237
rLAV EIA - July, p. 204
RNA viruses - Nov., p. 332
RotaShield - Sep., p. 258
rotavirus vaccines - Feb., p. 38; Sep., p. 258; Oct., p. 295
S-1153 - Apr., p. 105; July, p. 205
S-59 - Feb., p. 36
saquinavir (Fortovase) - Mar., p. 75; July, p. 203; Aug., p. 226, 236
SBAS4 - Dec., p. 358
SIV vaccines - Sep., p. 261
sodium dioctyl sulfosuccinate - July, p. 202
solvent/detergent inactivation - May, p. 142
sorivudine - June, p. 170
spermicides - Sep., p. 265
stem cells, ribozyme gene therapy - Feb., p. 43
SuperFluids CFI - Nov., p. 328
Supra-Molecular Biovector (SMBV) - May, p. 141; Dec., p. 361
Sustiva (use efavirenz)
Synagis (use palivizumab)
T-20 - Feb., p. 35; May, p. 140
T-cells, gene therapy - Feb., p. 35; Apr., p. 103
T22 - Mar., p. 74
TA-GW - May, p. 143
Taxol - Feb., p. 44
tetraazacyclotetradecane, phenylenebis-(methylene)]-bis- - Sep., p. 267
tetrachlorodecaoxygen (TCDO) - Nov., p. 331
TH 9407 - May, p. 143
Therapore - Feb., p. 46
thrombospondin - Feb., p. 43
thymosin alpha 1 (Zadaxin) - Feb., p. 38; Mar., p. 78; May, p. 134
transgenic plant vaccines - May, p. 139
TXU (anti-CD7)-pokeweed antiviral protein (TXU-PAP) - May, p. 136
vaccine adjuvants - Oct., p. 303
valacyclovir (Valtrex) - Sep., p. 264; Oct., p. 298
varicella-zoster virus vaccines - Feb., p. 42
Venezuelan equine enchephalits virus vaccine vectors - Dec., p. 362
vidarabine - Mar., p. 70
Videx (use DDI)
VIMRxyn - Feb., p. 40
VIR201 - Sep., p. 267
Viracept (use nelfinavir)
viral inactivation - Feb., p. 40, 41; Apr., p. 108; Oct., p. 294; Nov., p. 328, 332
Viramune (use nevirapine)
VircoGEN test - May, p. 139
Vistide (use cidofovir)
Vitravene (use fomivirsen)
VX-478 (use amprenavir)
VX-497 - Oct., p. 292
yellow fever virus vaccine vectors - July, p. 198; Dec., p. 359
Zadaxin (use thymosin alpha 1)
zanamivir (Relenza) - Apr., p. 104; Sep., p. 264; Nov., p. 332
Zerit (use D4T)
Ziagen (use abacavir)
Zidovudine (use AZT)
Zovirax (use acyclovir)
ZX0851 - July, p. 206